[go: up one dir, main page]

CA2458872A1 - Human ubiquitin-conjugating enzyme - Google Patents

Human ubiquitin-conjugating enzyme Download PDF

Info

Publication number
CA2458872A1
CA2458872A1 CA002458872A CA2458872A CA2458872A1 CA 2458872 A1 CA2458872 A1 CA 2458872A1 CA 002458872 A CA002458872 A CA 002458872A CA 2458872 A CA2458872 A CA 2458872A CA 2458872 A1 CA2458872 A1 CA 2458872A1
Authority
CA
Canada
Prior art keywords
conjugating enzyme
human ubiquitin
pharmaceutical composition
antibody
radioisotope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002458872A
Other languages
French (fr)
Other versions
CA2458872C (en
Inventor
Masato Horie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP06916397A external-priority patent/JP3646191B2/en
Application filed by Individual filed Critical Individual
Priority to CA2641565A priority Critical patent/CA2641565C/en
Publication of CA2458872A1 publication Critical patent/CA2458872A1/en
Application granted granted Critical
Publication of CA2458872C publication Critical patent/CA2458872C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed is a pharmaceutical composition for treating prostate cancer, the pharmaceutical composition comprising an antibody against human TMP-2 protein together with a pharmaceutically acceptable carrier. In one embodiment, the antibody is conjugated to a therapeutic moiety which can be a cytotoxic agent or a radioisotope.
CA002458872A 1996-03-19 1997-03-19 Human ubiquitin-conjugating enzyme Expired - Fee Related CA2458872C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2641565A CA2641565C (en) 1996-03-19 1997-03-19 Nel-related proteins type 1 and 2, and polynucleotides encoding them

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP6341096 1996-03-19
JP63410/1996 1996-03-19
JP69163/1997 1997-03-05
JP06916397A JP3646191B2 (en) 1996-03-19 1997-03-05 Human gene
CA002200371A CA2200371C (en) 1996-03-19 1997-03-19 Human npik gene

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002200371A Division CA2200371C (en) 1996-03-19 1997-03-19 Human npik gene

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2641565A Division CA2641565C (en) 1996-03-19 1997-03-19 Nel-related proteins type 1 and 2, and polynucleotides encoding them

Publications (2)

Publication Number Publication Date
CA2458872A1 true CA2458872A1 (en) 1997-09-19
CA2458872C CA2458872C (en) 2009-05-19

Family

ID=32474726

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002458872A Expired - Fee Related CA2458872C (en) 1996-03-19 1997-03-19 Human ubiquitin-conjugating enzyme

Country Status (1)

Country Link
CA (1) CA2458872C (en)

Also Published As

Publication number Publication date
CA2458872C (en) 2009-05-19

Similar Documents

Publication Publication Date Title
WO1994004702A3 (en) Improved detection and therapy of lesions with biotin/avidin conjugates
MXPA01011008A (en) Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases.
AP9801392A0 (en) Concentrated antibody preparation.
EP0926955A4 (en) Conjugates useful in the treatment of prostate cancer
EP0434765A4 (en) Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages
GB2276623A (en) Cytotoxic drug therapy
IL129356A0 (en) Conjugates useful in the treatment of prostate cancer
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
NZ512676A (en) A composition and method for the enhancement of the efficacy of drugs
PT837684E (en) PHARMACEUTICAL COMPOSITIONS BASED ON A DICLOFENAC AND THYOCOLCHOSIDE SALT
AU4830097A (en) Use of an extract of Cimicifuga
HUP0100350A3 (en) Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use
MY137303A (en) Methods for treating proliferative diseases
WO2003045429A3 (en) Anti-t cell immunotoxin fusion protein and its therapeutic use
ATE187890T1 (en) LIGAND DIRECTED ENZYME PRODRUG THERAPY
AU4789099A (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
WO1999021574A3 (en) Enhancement of morphogen activity
AU4953693A (en) Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
IL135520A0 (en) 8-azabicyclo [3.2.1.] octane-3-methanamine derivatives, their preparation and their therapeutic application
ZA973016B (en) Transdermally administered acetylcysteine as mucolytic agent.
AU6901191A (en) Pharmacologically active substance bpc, the process for its preparation and its use in the therapy
NZ501832A (en) Angiotensin-peptide carrier conjugates for treating diseases associated with the renin-angiotensin system
CA2458872A1 (en) Human ubiquitin-conjugating enzyme
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
WO2000014119A3 (en) Bifunctional antibodies and their use in targeting anti-tumour agents

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160321